PXN (Ab-272) Antibody

What is PXN (Ab-272) antibody and what epitope does it recognize?

PXN (Ab-272) antibody is a polyclonal antibody raised in rabbits that specifically recognizes the region surrounding serine 272 of the human paxillin protein. The immunogen used to generate this antibody is a synthesized non-phosphopeptide derived from human paxillin with the sequence around the serine 272 phosphorylation site (M-A-S-L-S) . This antibody is primarily used for detecting paxillin in its native state rather than specifically identifying the phosphorylated form, making it useful for total paxillin detection in cytoskeletal and focal adhesion studies.

What is the functional significance of paxillin in cellular research?

Paxillin (PXN) functions as a critical cytoskeletal protein involved in actin-membrane attachment at sites of cell adhesion to the extracellular matrix, specifically at focal adhesions . As a scaffold protein, paxillin recruits various structural and signaling molecules to these adhesion sites, functioning as a molecular switch that regulates cell migration, proliferation, and survival. Research utilizing PXN antibodies provides insights into fundamental cellular processes including cytoskeletal dynamics, mechanotransduction, and signal transduction pathways related to cancer progression and development.

What applications is PXN (Ab-272) antibody validated for?

The PXN (Ab-272) antibody has been validated for several research applications:

The antibody demonstrates reliable reactivity against human and mouse samples, making it suitable for comparative studies across these species .

How should I design experiments to distinguish between phosphorylated and non-phosphorylated paxillin?

When designing experiments to differentiate between phosphorylated and non-phosphorylated forms of paxillin, a dual-antibody approach is recommended. While PXN (Ab-272) detects total paxillin regardless of phosphorylation state, you should pair it with a phospho-specific antibody that exclusively recognizes paxillin when phosphorylated at Ser-272.

For optimal experimental design:

• Run parallel samples on separate blots or use stripping and reprobing techniques

• First probe with the phospho-specific antibody to detect phosphorylated paxillin

• Subsequently probe with PXN (Ab-272) to determine total paxillin levels

• Calculate the ratio of phosphorylated to total paxillin to assess relative phosphorylation state

This approach enables quantification of phosphorylation events while normalizing for variations in total protein expression across experimental conditions.

What are the recommended cell lysis conditions for preserving paxillin integrity in immunoblot studies?

For optimal preservation of paxillin integrity in cell lysates:

• Use a lysis buffer containing:

  • 50mM Tris-HCl (pH 7.4)

  • 150mM NaCl

  • 1% NP-40 or Triton X-100

  • 0.5% sodium deoxycholate

  • 1mM EDTA

  • Freshly added protease inhibitor cocktail

  • Phosphatase inhibitors (10mM NaF, 1mM Na₃VO₄) for phosphorylation studies

• Maintain samples at 4°C throughout processing to minimize degradation

• Include cytoskeletal stabilizing components when studying focal adhesion complexes

• Avoid excessive sonication which may disrupt protein-protein interactions

These conditions help maintain protein integrity while effectively solubilizing membrane-associated and cytoskeletal proteins like paxillin, ensuring reliable detection with PXN (Ab-272) antibody.

What controls should be included when using PXN (Ab-272) antibody in immunofluorescence studies?

When conducting immunofluorescence studies with PXN (Ab-272) antibody, the following controls are essential:

• Negative controls:

  • Secondary antibody-only control to assess non-specific binding

  • Isotype control (rabbit IgG at equivalent concentration) to evaluate background

  • Paxillin-null or knockdown cells to confirm specificity

• Positive controls:

  • Cell lines with known paxillin expression patterns (e.g., fibroblasts)

  • Co-staining with established focal adhesion markers (e.g., vinculin, FAK)

• Technical controls:

  • Peptide competition assay using the immunizing peptide

  • Comparison with alternative validated paxillin antibodies

These controls ensure the reliability of your staining pattern and help distinguish between true signal and artifacts, particularly important when studying discrete subcellular structures like focal adhesions.

How can PXN (Ab-272) antibody be utilized in chromatin immunoprecipitation studies examining transcriptional regulation?

While paxillin is primarily recognized for its cytoplasmic role in focal adhesions, emerging research indicates nuclear functions including transcriptional regulation. For chromatin immunoprecipitation (ChIP) studies with PXN (Ab-272):

• Optimize crosslinking conditions (1% formaldehyde for 10 minutes at room temperature is typically sufficient)

• Use nuclear fractionation protocols to enrich for nuclear paxillin

• Increase antibody concentration (typically 5-10μg per ChIP reaction)

• Implement more stringent washing conditions to reduce background

• Validate findings using alternative paxillin antibodies and reverse ChIP approaches

When analyzing ChIP data, consider:

• The transient nature of paxillin's nuclear localization

• Cell-cycle dependent variation in nuclear paxillin levels

• Possible indirect DNA association through transcription factor interactions

• Correlation with cytoplasmic signaling events that might trigger nuclear translocation

This application requires rigorous validation through complementary approaches such as reporter assays and DNA-protein interaction assays.

What approaches can be used to investigate paxillin phosphorylation dynamics in live cells?

To study dynamic phosphorylation of paxillin at serine 272 in living cells:

• FRET-based biosensors:

  • Design a paxillin construct with flanking fluorophores that undergo conformational change upon phosphorylation

  • Calibrate using phosphomimetic (S272D) and phospho-dead (S272A) mutants

  • Measure real-time changes in FRET efficiency during cellular processes

• Split-luciferase complementation:

  • Engineer paxillin and phospho-binding domain constructs with complementary luciferase fragments

  • Phosphorylation brings fragments together to produce bioluminescence

  • Quantify signal intensity as measure of phosphorylation state

• Phospho-specific antibody-based approaches:

  • Microinjection of fluorescently-labeled phospho-specific antibodies

  • Cell-permeable nanobodies against phosphorylated paxillin epitopes

  • SNAP/CLIP-tag labeling of paxillin combined with clickable phospho-sensors

While these approaches don't directly use PXN (Ab-272), they complement traditional fixed-cell immunofluorescence with this antibody by providing temporal resolution of phosphorylation events that cannot be captured in fixed samples.

How can mathematical modeling enhance interpretation of paxillin phosphorylation data obtained using PXN (Ab-272) antibody?

Mathematical modeling offers powerful tools for interpreting complex phosphorylation data from PXN (Ab-272) antibody studies:

• Kinetic modeling of phosphorylation dynamics:

  • Develop ordinary differential equation (ODE) models incorporating:

    • Kinase/phosphatase activities

    • Scaffolding protein interactions

    • Spatial constraints within focal adhesions

  • Parameterize using quantitative Western blot or mass spectrometry data

  • Predict temporal phosphorylation patterns under various conditions

• Spatial modeling of phosphorylation gradients:

  • Use partial differential equations to model diffusion-reaction processes

  • Incorporate data from immunofluorescence studies showing paxillin localization

  • Predict spatial distribution of phosphorylated paxillin within cellular structures

• Network modeling of signaling pathways:

  • Integrate paxillin phosphorylation data into larger signaling networks

  • Identify feedback/feedforward loops regulating phosphorylation

  • Predict system-level responses to perturbations

These computational approaches transform static antibody-derived data into dynamic models that generate testable hypotheses about regulatory mechanisms governing paxillin phosphorylation in complex cellular contexts.

What are common causes of false negative results when using PXN (Ab-272) antibody in Western blotting?

When encountering negative results with PXN (Ab-272) antibody in Western blotting, consider these potential issues:

• Sample preparation problems:

  • Insufficient cell lysis (paxillin is partially insoluble due to cytoskeletal association)

  • Protein degradation (use fresh protease inhibitors)

  • Loss of protein during precipitation steps

  • Inadequate protein denaturation before loading

• Technical issues:

  • Inefficient protein transfer (paxillin at 68kDa may require extended transfer times)

  • Excessive blocking (reduce concentration or duration)

  • Suboptimal antibody dilution (try 1:500 instead of 1:3000)

  • Insufficient incubation time (consider overnight at 4°C)

• Biological factors:

  • Low paxillin expression in certain cell types or conditions

  • Post-translational modifications masking the epitope

  • Species-specific variations affecting antibody recognition

A systematic troubleshooting approach involves testing positive controls (cell lines known to express paxillin), optimizing antibody concentration, and varying incubation conditions until signal is detected.

How should researchers interpret discrepancies between PXN (Ab-272) antibody results and phospho-specific paxillin antibody data?

Discrepancies between total paxillin (detected by PXN (Ab-272)) and phospho-paxillin antibody results require careful analysis:

• Possible biological explanations:

  • Changes in phosphorylation without changes in expression level

  • Altered availability of the epitope in different protein conformations

  • Subcellular redistribution affecting extraction efficiency

  • Phosphorylation-dependent protein stability differences

• Technical considerations:

  • Different antibody affinities requiring optimization of each antibody independently

  • Epitope masking by protein-protein interactions

  • Incomplete stripping between reprobes

  • Different detection sensitivities between antibodies

• Validation approaches:

  • Use multiple antibodies targeting different paxillin epitopes

  • Complement with mass spectrometry to quantify absolute phosphorylation levels

  • Employ genetic approaches (phospho-mimetic mutants) as controls

  • Perform in vitro kinase assays to establish baseline phosphorylation ratios

Importantly, discrepancies often reveal biologically significant phenomena rather than technical artifacts and may lead to novel insights into paxillin regulation.

What analysis methods are recommended for quantifying focal adhesion dynamics using PXN (Ab-272) antibody in immunofluorescence studies?

For quantitative analysis of focal adhesion dynamics using PXN (Ab-272) immunofluorescence:

• Image acquisition parameters:

  • Use consistent exposure settings across all experimental conditions

  • Capture Z-stacks to ensure complete sampling of focal adhesions

  • Employ multi-channel imaging to co-localize with other focal adhesion markers

• Image analysis approaches:

  • Automated focal adhesion segmentation using intensity thresholding

  • Measurement of parameters including:

    • Number of focal adhesions per cell

    • Average size and intensity of focal adhesions

    • Distance from cell periphery

    • Elongation factor (shape analysis)

  • Classification of focal adhesion subtypes based on morphology and composition

• Recommended software tools:

  • ImageJ with Focal Adhesion Analysis Server (FAAS) plugin

  • CellProfiler with custom analysis pipelines

  • MATLAB-based custom scripts for advanced analysis

• Statistical analysis:

  • Apply hierarchical statistical approaches that account for:

    • Multiple focal adhesions per cell

    • Multiple cells per treatment

    • Experiment-to-experiment variation

This quantitative approach transforms descriptive immunofluorescence data into objective metrics that can be statistically analyzed across experimental conditions.

How can PXN (Ab-272) antibody be utilized in studying cross-talk between integrin and growth factor signaling pathways?

PXN (Ab-272) antibody serves as a valuable tool for investigating signaling cross-talk:

• Experimental design strategies:

  • Stimulate cells with growth factors (EGF, PDGF) and analyze paxillin recruitment to focal adhesions

  • Manipulate integrin engagement through different matrix proteins and assess paxillin phosphorylation

  • Use pharmacological inhibitors of specific signaling nodes to identify convergence points

  • Create time-course experiments to establish signaling sequence

• Recommended methodological approach:

  • Combine PXN (Ab-272) antibody detection with phospho-specific antibodies

  • Perform proximity ligation assays to detect molecular interactions between signaling components

  • Use subcellular fractionation to track paxillin redistribution following stimulation

  • Implement siRNA knockdowns of pathway components to establish dependency

• Data interpretation framework:

  • Map temporal sequences of phosphorylation events

  • Identify cooperative versus antagonistic pathway interactions

  • Determine cell type-specific signaling variations

  • Correlate molecular events with functional outcomes (migration, proliferation)

This approach reveals paxillin's role as a pivotal integration point for diverse signaling inputs, providing insight into cellular decision-making mechanisms.

What experimental approaches can reveal the functional consequences of paxillin serine 272 phosphorylation in cell migration?

To elucidate the functional impact of serine 272 phosphorylation on cell migration:

• Genetic approaches:

  • Generate phospho-mimetic (S272D/E) and phospho-dead (S272A) paxillin mutants

  • Express in paxillin-null or knockdown backgrounds

  • Compare migration phenotypes using time-lapse microscopy

  • Analyze focal adhesion turnover rates in mutant-expressing cells

• Biochemical analyses:

  • Use PXN (Ab-272) antibody alongside phospho-specific antibodies

  • Perform immunoprecipitation to identify phosphorylation-dependent binding partners

  • Analyze cytoskeletal fraction association in phospho-mutants

  • Assess effects on downstream signaling effectors (e.g., Rho GTPases)

• Advanced imaging methods:

  • Implement FRAP (Fluorescence Recovery After Photobleaching) to measure focal adhesion dynamics

  • Use traction force microscopy to quantify cellular force generation

  • Apply super-resolution microscopy to analyze nanoscale organization at adhesion sites

  • Track individual adhesion assembly/disassembly events with high temporal resolution

• Correlation with physiological contexts:

  • Analyze phosphorylation levels during wound healing

  • Compare normal versus transformed cell behaviors

  • Examine tissue-specific phosphorylation patterns during development

These multifaceted approaches connect molecular phosphorylation events to cellular behaviors, establishing mechanistic understanding of paxillin's role in migration.

How should researchers account for cell cycle effects when analyzing paxillin expression and localization data?

Paxillin expression and localization vary throughout the cell cycle, creating potential confounding factors in experimental data:

• Experimental design considerations:

  • Synchronize cells at specific cell cycle stages using standard methods (double thymidine block, nocodazole arrest)

  • Use cell cycle markers (cyclins, Ki67) in co-staining experiments with PXN (Ab-272)

  • Implement live-cell cycle reporters (FUCCI system) for real-time correlation

  • Compare cell populations with similar cell cycle distributions across treatment groups

• Analysis strategies:

  • Apply cell cycle gating in flow cytometry experiments

  • Use computational approaches to classify cells by morphological features associated with cell cycle stages

  • Implement single-cell analysis to correlate paxillin metrics with cell cycle phase

  • Develop normalization methods based on cell cycle distribution

• Interpretation framework:

  • Distinguish cell cycle-dependent changes from treatment effects

  • Identify phase-specific roles of paxillin in cellular processes

  • Consider phase-specific vulnerabilities when targeting paxillin in disease contexts

  • Account for heterogeneous populations in tissue samples

This systematic approach prevents misattribution of cell cycle-related changes to experimental variables and reveals physiologically significant cell cycle-dependent regulation of paxillin.

What is the significance of nuclear paxillin localization in cancer research and how can it be reliably detected?

Nuclear paxillin represents an emerging area of research with implications for cancer biology:

• Biological significance:

  • Transcriptional co-regulation of genes involved in cell proliferation

  • Potential sequestration mechanism limiting cytoplasmic functions

  • Association with chromatin remodeling factors affecting epigenetic regulation

  • Correlation with cancer progression in multiple tumor types

• Reliable detection methods:

  • Nuclear/cytoplasmic fractionation followed by Western blotting with PXN (Ab-272)

  • Confocal microscopy with optical sectioning to distinguish true nuclear signal

  • Super-resolution techniques to resolve perinuclear versus intranuclear localization

  • Co-staining with nuclear envelope markers to define nuclear boundaries precisely

• Validation approaches:

  • Generate constructs with exogenous nuclear localization signals (NLS) as positive controls

  • Employ nuclear export inhibitors (Leptomycin B) to enhance nuclear accumulation

  • Use CRISPR-Cas9 to tag endogenous paxillin for live imaging

  • Confirm with multiple antibodies recognizing different paxillin epitopes

• Quantification methods:

  • Calculate nuclear-to-cytoplasmic ratio of paxillin immunofluorescence

  • Develop custom image analysis pipelines for automated quantification

  • Implement machine learning algorithms for unbiased classification

  • Correlate with cancer stage, grade, and patient outcomes in clinical samples

This comprehensive approach establishes nuclear paxillin as a legitimate biological phenomenon rather than an artifact, enabling investigation of its functional significance in cancer progression.